tradingkey.logo
tradingkey.logo

Seer Inc

SEER
View Detailed Chart
1.721USD
-0.004-0.23%
Market hours ETQuotes delayed by 15 min
153.47MMarket Cap
LossP/E TTM

Seer Inc

1.721
-0.004-0.23%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.23%

5 Days

-1.09%

1 Month

-17.66%

6 Months

-21.77%

Year to Date

-5.96%

1 Year

-4.92%

View Detailed Chart

TradingKey Stock Score of Seer Inc

Currency: USD Updated: 2026-03-25

Key Insights

Seer Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 6 out of 7 in the Office Equipment industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Seer Inc's Score

Industry at a Glance

Industry Ranking
6 / 7
Overall Ranking
235 / 4547
Industry
Office Equipment

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Seer Inc Highlights

StrengthsRisks
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.17M.
Fairly Valued
The company’s latest PB is 0.35, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 31.17M shares, decreasing 21.15% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.05M shares of this stock.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
3.000
Target Price
+52.28%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Seer Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Seer Inc Info

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Ticker SymbolSEER
CompanySeer Inc
CEOFarokhzad (Omid C)
Websitehttps://seer.bio/
KeyAI